FGTI-2734 mesylate |
| Catalog No.GC39276 |
El mesilato de FGTI-2734 es un inhibidor de farnesil transferasa (FT) y geranilgeranil transferasa-1 (GGT) mimético dual RAS C-terminal con IC50 de 250 nM y 520 nM para FT y GGT, respectivamente. El mesilato FGTI-2734 puede prevenir la localizaciÓn de membrana de KRAS, por lo tanto, resuelve el problema de resistencia a KRAS y frustra los tumores pancreÁticos derivados de pacientes con KRAS mutante.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2702297-24-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 mesylate can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors[1].
[1]. Kazi A, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res. 2019 Jun 21.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *